The American Heart Association (AHA) and American College of Cardiology (ACC), alongside nine other medical organizations, have released updated guidelines for managing dyslipidemia, a condition characterized by imbalanced blood lipids. The new recommendations, published on March 13, are the first update since 2018.
The updated guidelines focus on earlier intervention, personalized risk assessment, and clearer cholesterol targets to prevent cardiovascular disease events such as heart attacks and strokes.
Introduction to the New Guidelines
Published in journals including Circulation and the Journal of the American College of Cardiology, the updated guidelines aim to broaden prevention and treatment strategies for cardiovascular diseases, which remain a leading cause of death. The core emphasis is on proactive measures and individualized risk evaluation to address lipid abnormalities before serious health events occur.
Redefined Risk Assessment and Earlier Intervention
A significant change in the guidelines is the recommendation for cardiovascular risk assessment to begin for adults aged 30 and older, expanding from the previous age 40 and up. These assessments now consider both 10-year and 30-year risks for cardiovascular disease.
To facilitate this, the Predicting Risk of Cardiovascular Disease EVENTs (PREVENT) calculator has been introduced. This tool provides 10-year risk estimates for individuals aged 30 to 79 and 30-year risk estimates for those aged 30 to 59. The PREVENT calculator incorporates factors such as blood sugar and kidney function, in addition to traditional metrics like body mass index, cholesterol levels, and tobacco use.
Clinicians are encouraged to consider various "risk enhancers" during assessment, including:
- Family history of atherosclerosis
- Underlying conditions like rheumatoid arthritis, diabetes, advanced kidney disease, HIV, or cancer
- Life events such as early menopause or pregnancy complications (e.g., preeclampsia, gestational diabetes)
- Being overweight or obese
- Chronic inflammatory conditions
- Specific ancestries (e.g., South Asian or Filipino)
Expanded Diagnostic Tools
The updated guidelines recommend several additional diagnostic tests to enhance risk assessment beyond standard cholesterol panels:
- Lipoprotein(a) (Lp(a)) Testing: A one-time blood test for Lp(a) is now recommended for all adults. Lp(a) is a genetically determined type of cholesterol not typically included in routine lipid panels, and its levels remain stable throughout life. Elevated Lp(a) is associated with an increased inherited risk of heart attack, stroke, and aortic valve disease. High levels (e.g., >250 nmol/L) can indicate a two-fold increased risk. Currently, no specific treatments exist to lower Lp(a) directly, but identifying elevated levels informs overall risk management.
- Apolipoprotein B (ApoB) Testing: Measuring ApoB, a protein attached to artery-clogging particles, is suggested to provide a more accurate risk picture, particularly for individuals with high triglycerides, Type 2 diabetes, or cardiovascular-kidney-metabolic syndrome, or once LDL goals are met.
- Coronary Artery Calcium (CAC) Scan: This non-contrast CT scan detects existing plaque buildup in heart arteries. It is recommended for men aged 40 and older and women aged 45 and older who have a borderline or intermediate 10-year risk of heart attack or stroke to help tailor treatment plans.
- High-sensitivity C-reactive protein (hsCRP): This test measures inflammation and can be considered an additional risk enhancer.
Clarified Cholesterol Targets
The updated guidelines reintroduce specific LDL (low-density lipoprotein, or "bad" cholesterol) targets to provide clearer goals for patients and clinicians:
- For individuals at low risk of heart disease: LDL under 100 mg/dL
- For those at intermediate or higher risk: LDL under 70 mg/dL
- For individuals at very high risk or with existing heart disease: LDL under 55 mg/dL
These targets emphasize achieving lower LDL levels, especially in higher-risk populations.
Pillars of Prevention: Lifestyle Modifications
The guidelines emphasize five key lifestyle pillars for cardiovascular health across the lifespan:
- Heart-healthy diet: Prioritizing whole foods and limiting ultra-processed options and saturated fats.
- Regular physical activity: Aiming for at least 150 minutes of moderate-intensity exercise per week, complemented by strength training at least twice weekly.
- Avoiding tobacco: Eliminating all forms of tobacco use.
- Quality sleep: Recognizing sufficient sleep as a health priority.
- Maintaining a healthy weight: Achieving and sustaining a healthy body weight.
It is estimated that 80% to 90% of cardiovascular disease is linked to modifiable factors, underscoring the importance of these lifestyle adjustments.
Treatment Strategies
While lifestyle modifications are foundational, the guidelines also address medical interventions:
- Statins: These cholesterol-lowering medications remain a primary treatment. They are recommended for adults aged 30 and older with LDL cholesterol levels of 160 mg/dL or higher. Early initiation of statins may be considered for patients with higher risk factors to limit long-term exposure to elevated LDL cholesterol. Generic statins are widely available and cost-effective.
- Other Therapies: For individuals who do not respond well to statins or require further lipid reduction, other medications such as ezetimibe, bempedoic acid, and injectable PCSK9 monoclonal antibodies are options.
- Hypertriglyceridemia Treatment: Specific guidance is provided for high blood triglycerides. Extremely high levels (above 500 mg/dL) can indicate a genetic condition and elevate the risk of pancreatitis. New treatments like olezarsen and plozasiran are available for significant triglyceride reduction in such cases.
The guidelines also address treatment strategies for specific populations, including pregnant or breastfeeding individuals, adults aged 75 and older, and those with conditions such as diabetes, advanced kidney disease, HIV, or cancer.
Understanding Dyslipidemia
Dyslipidemia is a broad medical term describing any abnormality in blood lipids, including high levels of LDL cholesterol, low levels of HDL (high-density lipoprotein, or "good" cholesterol), and elevated triglycerides. These imbalances can lead to the gradual deposition of plaque in artery walls, a process known as atherosclerosis. This plaque can narrow arteries, restricting blood flow and potentially causing a heart attack or stroke. Dyslipidemia is often asymptomatic until a serious event occurs.
Childhood Screening Recommendations
Acknowledging that atherosclerosis can begin early in life, the guidelines recommend universal cholesterol screening for all children aged 9 to 11 years. This aims to identify familial hypercholesterolemia and lifestyle-related lipid abnormalities before symptoms develop, allowing for timely interventions and potentially reducing lifetime cardiovascular risk. Individuals with familial hypercholesterolemia are advised to begin screening around age 9 or earlier.
Rationale and Future Outlook
The rationale behind these updated guidelines is to enable earlier identification and management of cardiovascular risk factors.
Delaying treatment until later in life may mean significant damage has already occurred. Proactive prevention strategies initiated earlier in life are anticipated to positively impact the trajectory of cardiovascular disease and improve long-term health outcomes. Future recommendations may further emphasize lowering LDL cholesterol to below 55 mg/dL for individuals with moderate atherosclerosis, based on emerging research.